Clinical Trial Details


Research Study Summary

A multicenter, randomized, double-blind, placebo-controlled phase III study to evaluate the efficacy, safety and tolerability of Serelaxin when added to standard therapy in acute heart failure patients


The purpose of the study to evaluate the efficacy, safety and tolerability of intravenous infusion of serelaxin, when added to standard therapy, in acute heart failure (AHF) patients.

To Learn more

CW ID: 203072
Date Last Changed: November 6, 2014

Clinical Trial Snapshot

Both Male and Female
18 and up
Overall Status
Lead Sponsor
Novartis Pharmaceuticals Corporation
Facility Type


Courtney Lee
University of South Florida - Tampa General Hospital
1 Tampa General Circle
Tampa, FL 33606
Phone: (813)944-8240

View Map

DISCLAIMER: CenterWatch does not conduct clinical research. CenterWatch is a publishing company that posts clinical trials information on behalf of sponsor companies, contract research organizations, clinical research sites and other interested parties. This information is designed to help patients find clinical trials of interest and contact the research centers conducting the trials.